DELCATH SYSTEMS, INC. (NASDAQ:DCTH) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07. Submission of Matters to a Vote of Security Holders
On April6, 2018, Delcath Systems, Inc. (the “Company”), completed its Consent Solicitation in lieu of a Special Meeting of Shareholders. The following are the results of the Consent Solicitation.
| 1. | To approve an amendment to our amended and restated certificate of incorporation to increase our authorized shares of common stock from 500,000,000 to 1,000,000,000 |
|
VotesFor |
VotesAgainst |
Abstentions |
BrokerNon-Votes |
| 236,259,846 | 114,196,042 | 863,376 | -0- |
| 2. | To approve an amendment to our amended and restated certificate of incorporation to effect a reverse stock split of our common stock at a range of ratios from 1-for-100 to 1-for-500, in the discretion of the Board of Directors and to be announced by press release, and to grant authorization to the Board of Directors to determine, in its sole discretion, whether to implement the reverse stock split, as well as its specific timing (but not later than April6, 2019) |
|
VotesFor |
VotesAgainst |
Abstentions |
BrokerNon-Votes |
| 229,584,981 | 121,359,774 | 374,507 | -0- |
About DELCATH SYSTEMS, INC. (NASDAQ:DCTH)
Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.